創世紀(300083.SZ):鑽攻機截至目前已更新迭代至第七代 累計銷量超9萬台
格隆匯11月22日丨創世紀(300083.SZ)11月22日在投資者互動平台表示,鑽攻機是公司的拳頭產品,截至目前已更新迭代至第七代,累計銷量超90,000台,基本已實現下游3C核心用户的全面覆蓋,市場佔有率領跑行業,沉澱了良好的品牌口碑,2022年成功入選國家工信部製造業單項冠軍,已在3C領域躋身國產機牀企業第一梯隊。 手機中框使用鈦合金,導致加工時長加大,根據艾邦高分子數據,鈦合金手機中框加工時長約為鋁合金中框的3-4倍;未來,隨着鈦合金材料進一步在國內外各大手機品牌及產品類型中逐步滲透,對數控機牀需求的成長空間有望持續打開,公司也會受益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.